Business Context and Reporting Period
This Form 8-K is filed by Miragen Therapeutics, Inc. (not Viridian Therapeutics, Inc.) for the event date of November 12, 2020, with the report dated November 13, 2020. The company is a Delaware corporation trading on the Nasdaq Stock Market under the symbol MGEN.
Key Financial Metrics and Capital Structure
The filing does not provide revenue, profit, cash flow, margin, or debt figures. It focuses on capital structure changes resulting from a corporate action:
- Reverse Stock Split: Implemented a 1-for-15 reverse split of common stock.
- Post-Split Outstanding Shares: Approximately 3.91 million shares of common stock.
- Preferred Stock: Approximately 0.40 million shares of Series A Preferred stock outstanding.
- Conversion Potential: Series A Preferred stock is convertible into approximately 26.57 million shares of common stock (subject to approval and limitations).
- Stock Price Compliance: Regained compliance with Nasdaq Listing Rule 5550(a)(2) with a closing bid price of $1.00 or greater for 12 consecutive business days.
Material Changes Versus Prior Period
The primary material change is the reduction in the number of outstanding common shares and the proportional adjustment of conversion/exercise prices for options, warrants, and preferred stock due to the 1-for-15 reverse split. Additionally, the company resolved a prior non-compliance status regarding the minimum bid price requirement with Nasdaq.
Guidance, Outlook, and Risks
The filing contains no forward-looking guidance, revenue outlook, or management commentary regarding future operations. The primary risk addressed was the potential delisting due to failure to maintain a $1.00 minimum bid price, which has been resolved as of the filing date. The reverse split was authorized by stockholders at the Annual Meeting on May 21, 2020, and consented to on November 4, 2020.
Important Facts for Investor Verification
- Verify the new CUSIP number for the common stock: 60463E 202.
- Confirm the adjusted exercise prices of any outstanding stock options or warrants held, as these increased proportionally to the 1-for-15 split.
- Note that fractional shares were not issued; cash payments were made in lieu thereof.
- Monitor the conversion status of the 0.40 million Series A Preferred shares, which could significantly increase the common share count upon conversion.